Objective-Interaction of the activating sequence in thrombospondin-1 (TSP-1) with the conserved sequence (leucine-serinelysine-leucine [LSKL]) in the latency-associated peptide region of latent transforming growth factor (TGF)-β complex is important in regulating TGF-β1 activity. We aimed to assess the effect of blocking peptide LSKL on the progression of pre-established abdominal aortic aneurysm in angiotensin II-infused apolipoprotein E-deficient (ApoE −/− ) mice. Approach and Results-Abdominal aortic aneurysm was established in 3-month-old male ApoE −/− mice with subcutaneous infusion of angiotensin II for 28 days. After this, mice received LSKL peptide or control SLLK (serine-leucine-leucinelysine) peptide (4 mg/kg) via daily intraperitoneal injection for an additional 2 weeks. Administration of LSKL peptide promoted larger suprarenal aortic diameter, as determined by ultrasound and morphometric analysis, and stimulated more severe atherosclerosis within the aortic arch. In addition, mice receiving LSKL peptide exhibited elevated circulating proinflammatory cytokine levels and greater inflammatory cells within the suprarenal aorta compared with controls. Mice receiving LSKL peptide showed low plasma TGF-β1 activity and low levels of aortic tissue phosphorylated to total Smad2/3. Aortic gene expression of TGF-β receptor 1 (TGFBRI) and receptor 2 (TGFBRII), but not TGF-β1 and thrombospondin-1, were lower in mice receiving LSKL peptide than controls. LSKL peptide administration was associated with greater aortic elastin fragmentation and lower expression and activity of the TGF-β1-target gene lysyl oxidase like 1 (LOXL1).
A bdominal aortic aneurysm (AAA) is an important cause of mortality in older adults. There is considerable current interest in the pathogenesis of AAA because of the current lack of medical therapies for the condition. [1] [2] [3] Inflammation and excessive extracellular matrix (ECM) turnover are believed to play an important role in AAA progression. [1] [2] [3] Transforming growth factor (TGF)-β1 has been implicated in the regulation of inflammation and ECM remodeling. 4 We previously reported the downregulation of TGF-β receptor II (TGFBRII) in human AAA biopsies. 5 TGF-β1 has been reported to promote ascending aortic aneurysm in a mouse model of Marfan syndrome. 6, 7 Data from animal experiments examining AAA in a range of models, such as rat transplant, rat elastase, mouse calcium chloride, and mouse angiotensin II (AngII), however, suggest that TGF-β1 inhibits AAA development. [8] [9] [10] [11] TGF-β1 activation is a multistep process. The TGF-β1 precursor interacts with a latency-associated peptide and forms a complex called small latent complex. The small latent complex can also exist within the ECM as an inactive large latent complex bound to the latent TGF-β-binding protein. Secreted as a latent inactive procytokine complex, TGF-β1 must be activated to be recognized by cell surface receptors, as well as to trigger biological responses. 12 Thrombospondin (TSP-1) is a multifunctional ECM protein, which has been shown to be a major physiological activator of TGF-β1 in vivo. 13 This activation was observed to be dependent on the interaction between a specific TSP-1 sequence (lysine-argininephenylalanine-lysine; KRFK) and a conserved sequence (leucine-serine-lysine-leucine [LSKL]) near the amino terminus in the latency-associated peptide. 14 The lysine-arginine-phenylalanine-lysine sequence interacts with the February 2015 LSKL sequence to displace the latency-associated peptide and make the TGF-β1 accessible to its receptors, TGFBR I and II. 15 Previous studies have indicated that the conserved sequence (LSKL) is required for activation of TGF-β1 and that mimetic peptides of the sequence act as selective antagonists of TSP-1-mediated TGF-β1 activation in vitro and in vivo. [16] [17] [18] Previous reports suggest that LSKL peptide-mediated attenuation of TGF-β1 activation can prevent the progression of cardiac, hepatic, and renal interstitial fibrosis. 15, 17, 19 Complete deficiency of TGF-β1 pathway proteins has marked pathological effects, leading to in utero death. 20, 21 Because TSP-1 provides only one of the means by which TGF-β1 is activated, targeting this protein could have clinical relevance as a less severe strategy with potential to be applied to patients. [22] [23] [24] [25] We are aware of no previous studies which have examined the effect of blocking TSP-1-directed TGF-β1 activation on AAA. In the present study, we assessed the effect of systemic administration of LSKL peptide on progression of pre-established AAAs in the AngII-infused apolipoprotein E-deficient (ApoE −/− ) mouse model. We focussed on pre-established AAAs because the current clinical deficiency is the absence of therapeutic strategies to limit the progression of small, established AAAs in patients. 26 
Materials and Methods
The materials and methods are available in the online-only Data Supplement.
Results

LSKL Peptide Promoted Progression of AngII-Induced AAA
We used the previously established AngII infusion model to generate AAA in 30 male ApoE −/− mice. AngII was infused for 28 days. AAAs were monitored by periodic measurement of suprarenal and infrarenal aortic diameter by ultrasound. Baseline mean (±standard error) suprarenal aortic diameter was 0.76±0.01 mm and increased to 1.11±0.02 mm at day 28 (P<0.001). One mouse died as a result of aortic rupture and was excluded from the study. The remaining mice were then allocated to LSKL (experimental) or serine-leucine-leucine-lysine (SLLK; inert control) peptide groups such that similar mean maximum suprarenal aortic diameter was present in the 2 groups. The mice received their allocated peptide for a further 14 days.
Ultrasound-measured mean maximum suprarenal aortic diameter was significantly greater in the LSKL compared with the control group at day 42 (1.30±0.04 mm versus 1.15±0.03 mm; P=0.025; Figure 1A and Table 1) , that is, after 14 days of peptide administration. Morphometric assessment at killing demonstrated similar results with a mean maximum suprarenal aortic diameter in mice receiving LSKL peptide of 1.47±0.09 mm compared with 1.23±0.08 mm in control mice (P=0.031; Figure 1B ). The effect of the LSKL peptide was observed to be site-specific because mean maximum arch, thoracic, and infrarenal aortic diameters were not significantly different between experimental and control groups ( Figure 1B) .
Systolic blood pressure was measured at baseline, 14, 28, and 42 days. AngII infusion for 28 days caused a time-dependent increase in systolic blood pressure (mean systolic blood pressure Day 0: 104.40±1.70 mm Hg versus Day 28: 129.80±3.36 mm Hg; P=0.0001; Figure 1C ). Blood pressure was similar in mice allocated to the control and experimental groups at day 28 and dropped in both groups after cessation of AngII infusion ( Figure 1C ). Administration of LSKL peptide did not affect blood pressure by comparison to the control group (mean systolic blood pressure: 106.40±4.30 mm Hg versus108.24±3.26 mm Hg; P=0.992; Table 1 ). Heart rate was not altered throughout the study period (data not shown), and no difference in body weight was observed in the 2 groups during the study period (Table 1) .
LSKL Peptide Promoted Atherosclerosis in the AngII-Infused ApoE −/− Mouse Model
Atherosclerosis assessed by enface Sudan IV staining within the aortic arch was significantly greater in the LSKL compared with the control group, with a median staining area of 21.32% (interquartile range [IQR] 16.07-28.68) versus 6.41% (IQR 4.32-12.15; P=0.002; Figure 1D ). Levels of total cholesterol, low density lipoprotein, and high density lipoprotein were measured in a subset of mice at the end of the study to examine whether the peptide administration altered serum cholesterol concentration. Total cholesterol, low density lipoprotein, and high density lipoprotein were not significantly different in the 2 groups of mice (Table 1 ).
LSKL Promoted Suprarenal Aortic ECM Degeneration
Suprarenal aortic sections from mice administered LSKL peptide showed marked medial inflammation and adventitial atrophy (Figure 2A , i-ii). Verhoeff-Van Giesson staining demonstrated degradation of elastin filaments in both experimental and control groups ( Figure 2B) ; however, the degree of elastin filament degradation was higher in the LSKL peptide group (median grade 3.5 [IQR 2-4] versus 1 [IQR 1-2.5]; P=0.047; Figure 2C shows the grading). Assessment of picrosirus red staining for collagen within the suprarenal aortic tissue by polarization microscopy revealed significantly lower aortic wall collagen content in mice receiving LSKL peptide compared with those receiving the SLLK peptide (median picrosirus red staining area 39.65% [IQR 20.78-58] versus 74.75% [IQR 56.20-90.64]; P=0.017; Figure 2D and 2E).
LSKL Peptide Stimulated an Elevated Inflammatory Response
Systemic and local aortic inflammations were assessed by a multiplexed flow cytometric assay (cytometric bead array immunoassay) and immunohistochemistry, respectively. Comparison of plasma levels of proinflammatory cytokines between the 2 groups is shown in Table 2 . Administration of the LSKL peptide resulted in higher levels of circulating interleukin-6 (P=0.031) and monocyte chemoattractant protein-1 (P=0.015) compared with that in mice administered the control peptide. A similar trend was observed for plasma levels of interleukin-10, IFN-γ, TNF-α, and interleukin-12p70, but statistical significance could not be demonstrated ( Table 2) . Assessment of inflammatory infiltrates by immunohistochemistry showed significantly greater staining for CD3 + (T cells) and CD68 + (macrophage) cells within the suprarenal aorta of mice from the LSKL group. Median CD3 staining area was greater in the LSKL than the SLLK group ( Figure 3B and 3C, ii).
LSKL Peptide Decreased TGF-β1 Activity and Attenuated Smad Signaling
Platelet poor plasma was used to assess the levels of total and active TGF-β1. No observable change in plasma levels of total and latent TGF-β1 were detected during the 28-day AngII infusion period. At day 42, After administration of LSKL and SLLK peptides, total plasma TGF-β1 was found to be greater in both groups compared with that at day 28 ( Figure 4A , i).
There was no significant difference in total plasma TGF-β1 in the 2 groups ( Figure 4A ). In contrast, the mean concentration of active TGF-β1 was found to be significantly lower (0.10±0.01 pg/mL) in the plasma of mice receiving LSKL compared with that in plasma of mice receiving SLLK control peptide at day 42 (0.20±0.02 pg/mL; P=0.0001; Figure 4A , ii; Figure 4B , i, ii). In addition, immunohistochemical analysis revealed reduced nuclear localization of Smad4 protein within suprarenal aortas of LSKL-administered mice (11.10%, IQR 4.75-18.50) compared with control mice (29.50%, IQR 22.25-37.50; P=0.009; Figure 4C , i, ii). Relative mRNA expression of Smad4 was also lower within the suprarenal aorta of the LSKL group (0.89, IQR 0.45-1.22) compared with the SLLK-administered group (1.59, IQR 1.26-2.64; P=0.026; Table 3 ).
LSKL Peptide Administration Decreased Aortic Lysyl Oxidase Like 1 Expression
To assess the effect of TGF-β1 pathway inhibition by LSKL, we examined the expression of lysyl oxidase like 1 (LOXL1), connective tissue growth factor (CTCF), and plasminogen activator inhibitor-1 (PAI-1) genes, which have previously been reported to be important in matrix remodeling. [27] [28] [29] After normalizing to the expression of GAPDH, the relative median expression of the LOXL1 gene was significantly lower in the suprarenal aorta of the LSKL peptide group (0.35, IQR 0.14-0.67) compared with the control peptide group (0.89, IQR 0.44-2.15; P=0.049; Figure 5A ; Table 3 ). The relative expression of both CTCF and PAI-1 mRNA did not differ significantly between the LSKL and SLLK peptide groups (Table 3) .
Loxl activity was assessed in suprarenal aortic lysates and was shown to be significantly lower in mice receiving LSKL peptide ( Figure 5B and 5C).
Discussion
In the present study, we investigated the effect of blockade of TSP-1-dependent TGF-β1 activation on the progression of pre-established AAAs in the AngII-infused ApoE −/− mouse model.
Inhibition of TSP-1-dependent TGF-β1 activation with LSKL did not alter the aortic expression of TSP-1 and circulating total TGF-β1. We observed, however, that mice receiving LSKL peptide had decreased activation of TGF-β1 consistent with previous reports. 17, 19, [30] [31] [32] Our findings are similar to previous observations in a rat model of diabetes mellitus, where LSKL administration did not alter TSP-1 levels in myocardial extracts. 17 Expression of TGFBRI, TGFBRII, and Smad4 mRNA were significantly lower in mice receiving LSKL. The levels of cytoplasmic p-Smad2/3 and nuclear Smad4 proteins were lower in mice receiving LSKL, suggesting that LSKL limited TGF-β1 activation and in turn inhibited the TGF-β1 canonical Smad signaling pathway. The lower Smad2/3 and Smad4 expression observed in our study was in accordance with the previous reports, suggesting lower Smad signaling in TGF-β1 blocking experiments. 15, 30 Our observation of accelerated AAA progression after blockade of TSP-1-dependent TGF-β1 activation is in accordance with a study, which investigated established AAAs in rats using adenovirus-mediated overexpression of TGF-β1. 10 In that report, TGF-β1 overexpression induced by endovascular gene transfer or incubation with recombinant protein decreased proteolytic burden, slowed destruction of the arterial wall, and ultimately stabilized the AAA diameter. 10 These observations suggest a protective role for TGF-β1 in limiting AAA progression. A recent report by Wang et al 11 further supports the protective role of TGF-β1 in AAA pathogenesis. These investigators showed that a TGF-β blocking antibody promoted a dramatic increase in aortic aneurysm rupture in mice receiving AngII infusion. The findings suggest that TGF-β may be important in promoting matrix repair after aortic injury. In the present study, we observed an increase in circulating TGF-β1 levels 2 weeks after AngII infusion was completed, which could be a response to the aortic injury induced by AngII as the ECM enters a reparative phase. It should be noted that in disparity to the study by Wang et al, administration of TSP-1 blocking peptide did not promote aortic rupture. 11 There are several possible explanations for the disparity in findings of the 2 studies. First, the relative change in TGF-β activity is likely different in the 2 studies. A TGFβ blocking antibody would likely reduce TGF-β activity to a much greater degree than the TSP-1 blocking peptide used in the present study. Second, the timing of the interventions used in the two studies was different. Wang and colleagues tested the effect of blocking TGF-β during AAA induction at a stage when aortic rupture is much more likely within the AngII model. In the present study, the effect of a TSP-1 blocking peptide was examined in mice with established AAAs after AngII infusion was completed. A previous endovascular vascular smooth muscle cell seeding experiment in rats showed that stabilization of the diameter of expanding experimental AAAs was associated with increased expression and paracrine secretion of TGF-β1 within the aorta, supporting its ability to promote healing of AAAs. 33 These reports further support our observations of the protective role of TGF-β1 in AAA pathogenesis. . Leucine-serine-lysine-leucine (LSKL) peptide attenuates transforming growth factor-beta 1 (TGF-β1) activity and Smad signaling in angiotensin II (AngII)infused ApoE −/− mice. A, Plasma TGF-β1 activity is reduced in LSKL-injected mice. Total TGF-β1 (i) and TGF-β1 activity (ii) in platelet-poor samples collected at day 0, day 28, and day 42 after AngII infusion and 2 weeks of serine-leucine-leucine-lysine (SLLK) (n=14) or LSKL peptide (n=15) injection was measured using the TGF-β1 activity assay. Results are expressed as mean±SEM. (error bars). Statistical significance shown as *P<0.05; ***P<0.0001, LSKL versus SLLK. B, (i) Immunoblot for total and phosphorylated-Smad2/3 in extracts of suprarenal aortas. Compared with the SLLK-injected mice, Phospho-Smad2/3 levels were reduced in aortic lysates of AngII-infused ApoE −/− mice administered with LSKL peptide. (ii) Blots were quantified and analysed by densitometry, and the ratio of phospho-Smad2/3 was normalized to total-Smad2/3. Data presented as median and interquartile ranges (whiskers) and statistical significance shown as *P<0.05. C, (i) Immunohistochemical staining for Smad4 within a suprarenal aortic section of a mouse receiving LSKL peptide for 2 weeks after abdominal aortic aneurysm (AAA) induction by 28 days of AngII infusion. Suprarenal aortic sections were stained with antibody specific for active Smad4, color-developed with diaminobenzidine, and counterstained with hematoxylin. Compared with the SLLK-injected group, a reduced number of Smad4-positive cells was found within the suprarenal aortic sections of the LSKL group. Scale bar, 50 μm (*Lumen). (ii) Quantification of Smad4 immunoreactivity. Four to 5 fields were examined in each suprarenal aortic section, and the percent area stained for Smad4 was quantified as described in the Materials and Methods. AngII+SLLK (n=6) and AngII+LSKL (n=6). Data presented as median and interquartile range (whiskers) and statistical significance shown as **P<0.001.
Studies that contradict our findings are also reported. King et al 34 reported that administration of anti-TGF-β antibody inhibited AngII-induced AAA development in CXCL10deficient mice. Furthermore, reports using mice models of Marfan syndrome suggest that endogenous vascular TGF-β1 activity contributes to vessel dilatation and aneurysm formation within the thorax. 6 There are several possible explanations for the disparate findings. They could result from difference in the pathological features of different animal models. Marfan syndrome results from a monogenic defect, and the ECM remodeling in this disease is likely different to that induced by AngII administration. Also the presence of different proinflammatory cytokines may alter the overall effect of TGF-β1, for example, in the CXCL10-deficient mouse. 34 Reports regarding AngII-infused AAA formation are ambiguous. Some reports suggest that continuous infusion of Results were compared with the Mann-Whitney U test and expressed as relative expression of gene compared with glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
CTCF indicates connective tissue growth factor; IQR, interquartile range; LOXL, lysyl oxidases-like; LSKL, leucine-serine-lysine-leucine; N, sample number; PAI, plasminogen activator inhibitor; SLLK, serine-leucine-leucine-lysine; Smad, mothers against decapentaplegic homolog; TGF-b, transforming growth factor-beta; TGFBR, transforming growth factor beta receptor; and TSP, thrombospondin.
Statistical significance shown as *P<0.05. AngII is required for AAA progression in ApoE −/− mice. 35 In contrast, several previous studies suggest that aortic remodeling continues after AngII infusion is completed with continued increases in proteolytic enzymes and inflammation. 36, 37 Continued infusion of AngII is required for sustained increase in blood pressure, although previous studies suggest that AAA promoting properties of AngII are distinct to those stimulating hypertension. 38 In a recent study, we found that blood pressure immediately dropped when AngII infusion ceased at day 28 and returned to baseline by day 42; however, the aortic diameter continued to expand. 39 Blocking TSP-1-mediated TGF-β1 activation did not alter serum cholesterol levels but increased development of intimal atherosclerosis within the aortic arch of AngII-infused ApoE −/− mice. Recent evidence suggests that increasing plasma high density lipoprotein-c lowers the incidence of AngII-induced AAAs. 40, 41 These observations are in accordance with reports that TGF-β1 blocking strategies promote plaques with a rupture-prone phenotype in ApoE −/− mice. 42, 43 Atherosclerosis continued to progress in ApoE −/− mice after 2 weeks of AngII infusion, suggesting that a transient increase in AngII can have prolonged effect on atherosclerosis progression. 38 It is considered that atherosclerosis and AAA are 2 distinct pathological processes. 44 Our observations, however, underscore the protective role played by TGF-β1 during the healing phase of both AngII-induced AAA and atherosclerosis.
Analysis of systemic levels of proinflammatory cytokines showed that blocking TSP-1-mediated TGF-β1 activation was associated with only modest changes in systemic inflammation. In contrast, administration of LSKL peptide was associated with more marked increases in inflammatory cell accumulation within the suprarenal aorta and associated with focal elastin filament degradation and collagen reorganization. Macrophages have been suggested to be a major contributor to vascular wall destruction, 45 and source of proinflammatory cytokines, 46 implicated in the development of human and murine AAA. 47 Thus, our findings support an important role for TSP-1-mediated TGF-β1 activation in downregulating aortic inflammatory responses and preserving medial ECM. These data are supported by similar findings from other studies showing inflammatory cell infiltration in the absence of TGF-β1. 10, 11, 48 Recently, Dai et al 9 showed that Cyclosporine A induced TGF-β1 in samples of human AAAs in vitro and in animal models of AAA in vivo. Administration of Cyclosporine A for 7 days stabilized already formed AAAs with concomitant downregulation of vascular wall inflammation, suggesting that pharmacological induction of TGF-β1 is a potential approach to induce AAA stabilization.
Elastin and collagen are important structural elements of the aortic wall. Attenuation of TGF-β1 activity in mice receiving LSKL was associated with reduced collagen deposition and increased elastin filament degradation. Elastin degradation seems to occur in the early stages of AAA development. 49, 50 We observed elastin degradation in mice that received both SLLK and LSKL peptides; however, elastin degradation was more marked in animals administered LSKL. Our findings suggest that acceleration of AAA progression represents a failure to repair the ECM in the absence of TSP-1-mediated TGF-β1 activation. Recently, it was shown that peri-aortic application of the adipokine leptin reduced TGF-β1 expression in the aorta of ApoE −/− mice and resulted in enhanced medial ECM degradation and AAA expansion in AngII-infused mice. 51 Reports suggest that collagen synthesis increases during the early stages of AAA development, and at later stages, degradation exceeds synthesis, leading to continued aneurysm expansion and eventual rupture. 52, 53 Overall, our findings suggest that blocking TSP-1-mediated TGF-β1 activation leads to enhanced elastin degradation and reduced collagen deposition in the aortas of ApoE −/− mice. These observations suggest that TGF-β1 plays an important role in the healing phase of pre-established AAAs.
We assessed the effect of blocking TGF-β1 signaling on the expression of 3 genes involved in ECM remodeling, namely, LOXL1, CTCF, and PAI-1. 28, 29, 54 Expression of CTCF and PAI-1 was not significantly altered after LSKLpeptide administration. This observation is supported by the previous report that basal expression of some fibrotic genes, such as CTCF and syndecans4, are independent of the TGF-β1 signaling pathway. 55 Additionally, TGF-β1-stimulated PAI-1 expression in vascular smooth muscle cell was found to require both epithelial growth factor receptor and Rho/ ROCK signaling, suggesting that Smad phosphorylation in the absence of epithelial growth factor receptor signaling is not sufficient to initiate PAI-1 expression. 56 The mRNA expression of LOXL1 was significantly reduced within the suprarenal aortas of mice receiving LSKL peptide in keeping with a previous study. 27 Previous reports show that mutation of LOX or LOXL1 genes leads to a poorly formed vessel wall that is prone to breakdown and aneurysm. [57] [58] [59] Because Loxl1 localizes specifically to sites of elastogenesis, it plays a crucial role in elastic fiber maintenance and serves both as a cross-linking enzyme and an element of the scaffold to ensure spatially defined deposition of elastin. 57 Decrease of Lox activity has been associated with aneurysm development and plaque rupture. 60 Our gene expression analysis showed that LSKL peptide administration significantly attenuated Loxl1 mRNA, protein, and activity within the aorta of AngII-infused ApoE −/− mice. These findings may explain the limitation of aortic reparative response in mice receiving LSKL peptide.
The present study has several strengths and weaknesses. Unlike several other studies assessing the effects of TGF-β1 within the AngII-infused AAA model, we examined the effect of TSP-1-mediated TGF-β1 activation on progression of established AAAs. Thus, relating our findings to previous studies is not straightforward. The advantage of this approach is that it is likely more relevant to the clinical situation. There is no current drug-based therapy which is effective at limiting AAA progression; hence, identifying treatment targets to limit AAA progression is important. As with all animal model studies, however, the translation of the current findings to humans is unknown, but supported by our previous finding of downregulation of TGF-β1 pathway members in human AAA samples. 5 Inhibition of TSP-1-mediated TGF-β1 activation modestly promoted AAA progression in the present study. Other studies will be needed to establish whether similar findings are evident in other preclinical models with differing aneurysm severities. Another limitation of the present study is that we focused on the canonical Smad pathway, and this pathway is not unique to TGF-β1. We were not able to examine the effects of the administered peptides on the noncanonical pathway.
In summary, this study suggests that inhibition of TSP-1-mediated TGF-β1 activation promotes AAA progression through favouring aortic infiltration of inflammatory cells and defective ECM repair.
